TransCode Therapeutics (RNAZ) Competitors $7.60 +0.04 (+0.53%) As of 10:27 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. LSTA, MIRA, RLMD, ABVC, NRSN, CASI, KALA, QTTB, ENLV, and XFORShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Lisata Therapeutics (LSTA), MIRA Pharmaceuticals (MIRA), Relmada Therapeutics (RLMD), ABVC BioPharma (ABVC), NeuroSense Therapeutics (NRSN), CASI Pharmaceuticals (CASI), KALA BIO (KALA), Q32 Bio (QTTB), Enlivex Therapeutics (ENLV), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors Lisata Therapeutics MIRA Pharmaceuticals Relmada Therapeutics ABVC BioPharma NeuroSense Therapeutics CASI Pharmaceuticals KALA BIO Q32 Bio Enlivex Therapeutics X4 Pharmaceuticals Lisata Therapeutics (NASDAQ:LSTA) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Is LSTA or RNAZ more profitable? Lisata Therapeutics' return on equity of -51.19% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -51.19% -45.16% TransCode Therapeutics N/A -649.03%-281.34% Does the MarketBeat Community believe in LSTA or RNAZ? TransCode Therapeutics received 2 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 93.33% of users gave Lisata Therapeutics an outperform vote while only 88.89% of users gave TransCode Therapeutics an outperform vote. CompanyUnderperformOutperformLisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67%TransCode TherapeuticsOutperform Votes1688.89% Underperform Votes211.11% Do insiders & institutionals have more ownership in LSTA or RNAZ? 8.9% of Lisata Therapeutics shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher earnings and valuation, LSTA or RNAZ? TransCode Therapeutics has lower revenue, but higher earnings than Lisata Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M21.80-$20.84M-$2.30-1.10TransCode TherapeuticsN/AN/A-$18.55MN/AN/A Does the media prefer LSTA or RNAZ? In the previous week, Lisata Therapeutics had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.87 beat Lisata Therapeutics' score of 0.94 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lisata Therapeutics Positive TransCode Therapeutics Very Positive Do analysts prefer LSTA or RNAZ? Lisata Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 492.89%. TransCode Therapeutics has a consensus target price of $280.00, suggesting a potential upside of 3,545.83%. Given TransCode Therapeutics' higher possible upside, analysts clearly believe TransCode Therapeutics is more favorable than Lisata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, LSTA or RNAZ? Lisata Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, TransCode Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. SummaryLisata Therapeutics beats TransCode Therapeutics on 7 of the 12 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.40M$6.91B$5.59B$8.59BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.8127.1220.00Price / SalesN/A254.61419.48155.53Price / CashN/A65.8538.2534.64Price / Book0.096.567.104.69Net Income-$18.55M$143.93M$3.23B$247.88M7 Day Performance6.37%3.35%2.45%2.34%1 Month Performance-23.21%10.64%8.65%6.06%1 Year Performance-99.98%3.73%31.26%13.59% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.5955 of 5 stars$7.60+0.5%$280.00+3,584.2%-100.0%$6.33MN/A0.009Positive NewsLSTALisata Therapeutics2.4806 of 5 stars$2.74+5.0%$15.00+447.4%-33.0%$23.61M$1M-1.0930News CoverageMIRAMIRA Pharmaceuticals3.38 of 5 stars$1.39+3.0%$14.00+907.2%+61.3%$23.52MN/A-2.482Positive NewsShort Interest ↓RLMDRelmada Therapeutics4.8177 of 5 stars$0.71-5.5%$4.25+499.9%-74.8%$23.52MN/A-0.2510Positive NewsABVCABVC BioPharma0.5678 of 5 stars$1.54+12.4%N/A+96.5%$23.27M$508.38K-1.7930NRSNNeuroSense Therapeutics2.2129 of 5 stars$1.69+9.7%$14.00+728.4%+146.5%$23.10MN/A-2.6410Gap UpCASICASI Pharmaceuticals4.2383 of 5 stars$1.87-1.3%$4.00+114.5%-44.7%$22.94M$31.37M-0.84180KALAKALA BIO3.9006 of 5 stars$3.52-5.4%$13.50+283.5%-30.7%$22.71M$3.89M-0.2830Positive NewsGap UpQTTBQ32 Bio3.4369 of 5 stars$1.83+5.8%$24.71+1,250.5%-91.5%$22.32M-$6.65M-0.1339Positive NewsShort Interest ↓ENLVEnlivex Therapeutics3.4753 of 5 stars$0.94+0.4%$10.00+963.8%-33.7%$22.23MN/A-0.9670News CoverageUpcoming EarningsXFORX4 Pharmaceuticals4.3682 of 5 stars$3.81+12.1%$72.33+1,798.5%-89.8%$22.06M$31.36M-42.3380Short Interest ↑Analyst RevisionGap UpHigh Trading Volume Related Companies and Tools Related Companies Lisata Therapeutics Competitors MIRA Pharmaceuticals Competitors Relmada Therapeutics Competitors ABVC BioPharma Competitors NeuroSense Therapeutics Competitors CASI Pharmaceuticals Competitors KALA BIO Competitors Q32 Bio Competitors Enlivex Therapeutics Competitors X4 Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNAZ Stock Free RNAZ Stock Alerts